Hypersound Medical, a medical technology innovator developing non-invasive, ultrasound-based therapies for chronic and acute pain, announced positive responses from the first human participants in its early-stage clinical trial evaluating the company’s novel RF-based pain management device.
In the initial cohort, 80% of treated individuals experienced measurable pain reduction following treatment with the Hypersound device.
In the chronic pain management landscape where many existing therapies fall short or carry significant risks an 80% response rate in first-in-human data represents a meaningful and encouraging clinical signal.
“This milestone marks an important validation of the Hypersound platform,” saidTim Dickman, Hypersound CEO. “Early human data demonstrating clinically meaningful pain reduction supports our belief that non-invasive, non-opioid technologies can reshape the future of pain care.”
Key Milestone Highlights:
-
First-in-human validation of the Hypersound RF pain management platform
-
80% of participants reported clinically meaningful pain reduction
-
Non-invasive, non-opioid treatment with no surgical intervention required
-
A defined path forward toward expanded clinical trials and future regulatory milestones
The Hypersound device is designed to deliver targeted radiofrequency (RF) energy to address chronic pain without the need for opioids or invasive procedures. These early results provide a foundation for further clinical evaluation and broader validation.
Hypersound extends its sincere gratitude to the trial participants, the clinical investigators, and its advisory team for their commitment and scientific rigor in reaching this milestone.
With this encouraging early data, the company is preparing for expanded studies as it advances toward regulatory and commercialization objectives.
About Hypersound
Hypersound is a medical technology company focused on advancing non-invasive, RF-based solutions for chronic pain management. The company is committed to developing safe, effective alternatives to traditional pain therapies.